Xiaonan Qiu

Xiaonan Qiu

Auto-generated profile, based on publicly available information

Xiaonan Qiu

Department of Dermatology, Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in The FASEB Journal
Verified
Journal Article
Closed access
CGChipeng Guo
Chipeng Guo
LLLizhu Liang
Lizhu Liang
JZJingbin Zheng
Jingbin Zheng
YXYang Xie
Yang Xie
XQXiaonan Qiu
Xiaonan Qiu
LWLiangchun Wang
Liangchun Wang

4 March 2025 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
GGGanlin Gu
Ganlin Gu
LJLiyue Ji
Liyue Ji
XQXiaonan Qiu
Xiaonan Qiu
JZJing Zhang
Jing Zhang
Background: Linear scars, resulting from surgical incisions or traumatic injuries, can pose both aesthetic and functional dilemmas. Ablative fractional CO₂ laser (AFCL) therapy has been recognized for its ability to enhance the appearance and flexibility of scars; however, the ideal timing for such treatments remains a subject of debate.Aims: This study retrospectively evaluates the effectiveness of AFCL in treating linear atrophic and hypertrophic scars, with a focus on identifying the optimal timing to achieve the best possible outcomes.Methods: Patients who underwent treatment for linear scars using AFCL at our hospital between January 2022 and July 2024 were included in the study. Participants were categorized into two groups: those with atrophic scars and those with hypertrophic scars. Hypertrophic scars were assessed using the Vancouver Scar Scale (VSS), whereas atrophic scars were evaluated with the Scar Cosmesis Assessment and Rating (SCAR) scale. Furthermore, considering the timing of scar formation—with a six‐month period as the threshold—two subgroups were categorized as early treatment and late treatment. The disparities in scar improvement rates were then computed and subjected to analysis.Results: Among 55 patients, 31 had atrophic scars and 24 had hypertrophic scars. AFCL treatment significantly improved clinical scores in both groups. The SCAR score for atrophic scars decreased from 6.50 (SD 1.31) to 4.92 (SD 1.71) (p < 0.001), and the VSS score for hypertrophic scars decreased from 6.02 (SD 0.46) to 2.73 (SD 0.39) (p < 0.001). The early‐treatment subgroup showed a 35.38% (SD 24.54%) improvement in atrophic scars, significantly higher than the 12.53% (SD 25.65%) in the late‐treatment subgroup (p = 0.018). No significant timing effect was found for hypertrophic scars (p = 0.764).Conclusion: AFCL is an effective treatment for linear scars. Early intervention, specifically within the first 6 months, leads to superior outcomes for atrophic scars. In contrast, the timing of treatment is less critical for hypertrophic scars.Trial Registration: Chinese clinical trial registry: Registration no. ChiCTR2400092038